Back to today’s briefing

Story perspectives

FDA Approves First New Antibiotic for UTIs in 30 Years

3/26/2025

50 11

Summary

Story summary

In a groundbreaking move, the FDA has greenlit Blujepa, marking the first new antibiotic for uncomplicated urinary tract infections in nearly three decades. Developed by GSK, this innovative treatment specifically targets E. coli and has demonstrated effectiveness in 50-58% of cases during clinical trials. Expect its arrival in the U.S. by late 2025.

1 of 1

Story summary

In a groundbreaking move, the FDA has greenlit Blujepa, marking the first new antibiotic for uncomplicated urinary tract infections in nearly three decades. Developed by GSK, this innovative treatment specifically targets E. coli and has demonstrated effectiveness in 50-58% of cases during clinical trials. Expect its arrival in the U.S. by late 2025.